card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Advancing oncology research

Comprehensive blood-based protein biomarker testing for enhanced drug discovery and clinical trials
Advancing oncology research
Home / Insights / Advancing oncology research

Rules-Based Medicine (RBM) offers a broad menu of proteins associated with various processes in the development of cancer, including oncogenesis, immune or inflammatory responses, cell proliferation and metabolites secreted from tumor tissue.  Our protein biomarkers are selected using peer-reviewed research and aim to expedite development of targeted cancer therapeutics. We offer multiplexed Luminex® assays, ultrasensitive Simoa® assays and the Olink® Target 48 Cytokine panel. RBM also offers TruCulture®, our proprietary whole blood collection and culture system.

 


Download Document